BIIB
Biogen
$205.63
▼ 0.3%Updated Today 11:30 AM ET
BIIB at a glance — five pillars scored 0–100 from real filed financials.
Overall: Neutral · 49/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▲ Up 55.4% over the last 12 months
Market Cap
$31.91B
P/E
22.5x
Forward P/E (est.)
24.47x
ROE
7.5%
Revenue Growth
1.2%
EPS Growth
-8.1%
Profit Margin
13.8%
FCF Yield
6.8%
Debt / Equity
0.34x
ROIC
11.0%
Interest Coverage
10.62x
Current Ratio
3.06x
Dividend Yield
—
Implied Growth (rev. DCF)
2.4%
Rating Score
49/100
Biogen (BIIB) is a large-cap company in the Biotechnology industry, part of the Health Care sector of the S&P 500, with a market value around $31.91B.
In its latest reported year it generated about $9.89B in revenue and $1.29B in net profit.
Our model rates BIIB Neutral (49/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
Some durable-advantage evidence, but not across the board — dig into which ingredient is weak and whether it's cyclical or structural.
86.5% average over the last 3 years
±0.2 pts around 86.7% across 5 years
grew in 4 of the last 9 year-over-year periods
positive in 10 of 10 years
11.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what BIIB's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. BIIB trades near $205.63, above its 50-day average ($195.77) and 200-day average ($177.63). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 67 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. BIIB's is $6.82 (~3.3% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month BIIB found buyers near $192.18 (support) and sellers near $219.72 (resistance); its 52-week range is $121.05–$219.72. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 1.0× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
-2.6%
Revenue moved from $11.45B in 2016 to $9.89B in 2025, a -1.6% compound annual growth rate. The most recent year was roughly flat (1.2%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
75.5%
Operating Margin
17.5%
Net Margin
13.1%
ROE
7.5%
Biogen keeps about 13.8% of each sales dollar as net profit, with a 75.5% gross margin and 17.5% operating margin. Return on equity is 7.5% and return on invested capital about 11.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$6.29B
Net Debt
$3.37B
Net Debt / EBITDA
—
Debt / Equity
0.34x
Leverage: debt-to-equity is 0.3x, and operating profit covers interest about 10.6x, with a current ratio of 3.1x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $6.29B of total debt against $2.91B of cash.
Operating CF
$2.20B
Free Cash Flow
$2.05B
FCF Margin
20.7%
In the latest year Biogen produced about $2.20B of operating cash flow and $2.05B of free cash flow after capital spending. That is a free-cash-flow yield of about 6.8% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
22.5x
P/S
2.92x
P/B
1.51x
EV / EBITDA
—
BIIB trades at 22.5x trailing earnings (about 24.5x on estimated forward earnings), 2.9x sales, and 1.5x book value. Reverse-engineering today's price implies the market expects roughly 2.4% long-term free-cash-flow growth. That is a fairly typical valuation for a profitable company.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$203.77
Current price
$205.63
Starting FCF (latest 10-K)
$2.05B
Growth, years 1–5
1.2%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where BIIB sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How BIIB stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), BIIB ranks #47 of 324 by our overall rating. It trades at a discount versus the sector on earnings (22.5x P/E vs. 27.3x median) with a lower return on equity (7.5% vs. 14.1%) and slower revenue growth (1.2% vs. 7.6%).
P/E vs sector
22.5x
median 27.3x
ROE vs sector
7.5%
median 14.1%
Growth vs sector
1.2%
median 7.6%
Sector rank
#47
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $205.63 today · expected CAGR -8% – 1%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $10.19B | $10.49B | $10.81B | $11.13B | $11.47B |
| Net income | $1.32B | $1.36B | $1.41B | $1.45B | $1.49B |
| EPS | $8.53 | $8.79 | $9.05 | $9.33 | $9.61 |
| Share price (low) | $119.49 | $123.07 | $126.77 | $130.57 | $134.49 |
| Share price (high) | $196.30 | $202.19 | $208.26 | $214.51 | $220.94 |
| CAGR (low–high) | -42% / -5% | -23% / -1% | -15% / 0% | -11% / 1% | -8% / 1% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for BIIB:
- Healthy free-cash-flow yield (~6.8%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.3x) lowers risk.
The case against BIIB:
- Revenue growth is slow (1.2%), limiting the upside engine.
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Growth risk — sluggish revenue (1.2%) leaves little margin for execution missteps.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: Biogen is a large-cap health care business growing at a mature pace, with solid profitability, and a sound balance sheet. It trades at 22.5x earnings, which our model scores Neutral (49/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 43 Wall Street analysts covering BIIB recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Analysts have turned more positive over the last three months (+12 pts of buy ratings).
Latest SEC Filings
BIIB's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
BIIB — frequently asked questions
Is BIIB a good stock to buy?
We don't give buy or sell advice. Our model rates Biogen Neutral (49/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is BIIB's rating on The Stocks School?
Biogen currently scores 49/100 (Neutral) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does BIIB's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Biogen's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for BIIB calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this BIIB analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell BIIB. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.